3[1]Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase like activities. Circulation, 2000, 30:2510
4[2]McElveen J, Mackness MI, Colley CM, et al. Distribution of paraoxon hydrolitic activity in the serum of patients after myocardial infarction, Clin Chem, 1986, 32:671
5[3]Mackness MI, Harty D, Bhatnagar D, et al. Serum paraoxonase activity in familial hypercholesterolaemia and insulin-dependent diabetes mellitus. Atherosclerosis, 1991, 86:193
6[4]Furlong CE, Richter RJ, Seidel SL, et al. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolisis of the insecticide metabolites chlorpyifos oxon and paraoxon. Am J Hum Genet, 1988, 43:230
7[5]Steinberg D. Lipoproteins and atherosclerosis:a look back and a look ahead. Arteriosclerosis, 1983, 3:283
8[6]Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol:Modification of low-density lipoprotein that increase its atherogenicity. New England J Medicine, 1989, 320(14):915
9[7]Gordon D. In:Durrington PN(ed). HDL:Where should the clinician stand? London:Mark Allen Publishing, 1992,17
10[8]Klimov AN, Kozhemyakin LA, Pleskov VM, et al. Antioxidative effect of high density lipoprotein in the oxidation of low density lipoprotein. Bull Exp Biol Med, 1987, 103:550
